Radnet (RDNT) AI Stock Analysis

• Market Cap: $6.05B
• Dividend Yield: N/A
• Average Volume (3M): 631.99K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.30
• Revenue Growth: 11.09%
• EPS Growth: -165.89%
• Country: US
• Employees: 11,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.20
• Shares Outstanding: 77,101,600
• 10 Day Avg. Volume: 572,866
• 30 Day Avg. Volume: 631,993
• PEG Ratio: -90.19
• Price to Book (P/B): 5.65
• Price to Sales (P/S): 2.79
• P/FCF Ratio: 3.95K
• Enterprise Value/Market Cap: 0.92
• Enterprise Value/Revenue: 2.82
• Enterprise Value/Gross Profit: 24.66
• Enterprise Value/Ebitda: 23.16
• 1Y Price Target: $79.25
• Price Target Upside: 1.20% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 67 Neutral
• Price Target: $88.00 ▲(12.37% Upside)

RadNet, Inc. shows strong technical momentum and positive earnings call sentiment, with record-breaking revenue and strategic growth initiatives. However, the company's valuation is impacted by negative profitability, and financial performance is constrained by leverage and margin challenges.

Positive Factors

Revenue Growth

Strong revenue growth reflects successful strategic initiatives and market demand, indicating robust business expansion potential.

Digital Health Expansion

Significant growth in digital health and AI revenue suggests a strong position in a rapidly evolving sector, enhancing long-term prospects.

Strategic Acquisition

The acquisition of CIMAR UK enhances RadNet's technological capabilities and market reach, supporting future growth in connected imaging-based care.

Negative Factors

High Leverage

High leverage can limit financial flexibility and increase risk, potentially impacting long-term financial stability and investment capacity.

Profitability Concerns

Negative profitability indicates challenges in cost management and pricing, which could hinder sustainable growth and shareholder returns.

Labor Market Challenges

Labor market challenges can affect operational efficiency and service delivery, potentially limiting the company's ability to scale effectively.

Radnet Business Overview & Revenue Model

Company Description

Radnet, Inc. (RDNT) is a leading national provider of outpatient diagnostic imaging services in the United States. The company operates a network of imaging centers and offers a comprehensive range of services including MRI, CT scans, ultrasound, and X-ray. Radnet is focused on delivering high-quality imaging services, leveraging advanced technology and a team of specialized radiologists. The company is also committed to providing value-based care, emphasizing patient-centered services and efficient imaging solutions.

How the Company Makes Money

Radnet generates revenue primarily through the provision of diagnostic imaging services to patients, which are often reimbursed by insurance providers, including Medicare and Medicaid. The company operates a fee-for-service model, where it bills patients or their insurance for each imaging procedure performed. Key revenue streams include payments for various imaging modalities such as MRI, CT, and ultrasound services. Additionally, Radnet benefits from strategic partnerships with healthcare providers and payers that facilitate patient referrals and enhance service delivery. The company may also engage in value-based care contracts that incentivize the delivery of cost-effective imaging services, contributing to its overall earnings.

Radnet Financial Statement Overview

Summary

Radnet demonstrates moderate revenue growth and strong cash flow generation, but profitability and leverage remain concerns. The company faces challenges in maintaining margins and managing debt levels, which could impact future financial stability.

Income Statement

Radnet's income statement shows moderate revenue growth with a 3.24% increase in TTM, but profitability is a concern with a negative net profit margin of -0.65%. The gross profit margin has decreased from previous years, indicating rising costs or pricing pressures. EBIT and EBITDA margins have also declined, reflecting operational challenges.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 1.75, indicating significant leverage, though it has improved from prior years. Return on equity is negative, suggesting inefficiencies in generating returns for shareholders. The equity ratio is relatively stable, but the high leverage poses risks.

Cash Flow

Cash flow analysis shows strong free cash flow growth of 95.27% in TTM, indicating improved cash generation. The operating cash flow to net income ratio is healthy, but the free cash flow to net income ratio suggests that cash flow is not fully translating into profitability. Overall, cash flow management appears robust.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.97B	1.83B	1.62B	1.43B	1.32B	1.07B
Gross Profit	225.22M	249.12M	221.39M	165.72M	191.80M	105.94M
EBITDA	239.79M	262.55M	292.79M	278.53M	278.37M	199.74M
Net Income	-12.71M	2.79M	3.04M	10.65M	24.73M	-14.84M
Balance Sheet
Total Assets	3.67B	3.29B	2.69B	2.43B	2.06B	1.79B
Cash, Cash Equivalents and Short-Term Investments	804.72M	740.02M	342.57M	127.83M	134.61M	102.02M
Total Debt	1.85B	1.73B	1.49B	1.51B	1.40B	1.18B
Total Liabilities	2.35B	2.15B	1.88B	1.94B	1.71B	1.53B
Stockholders Equity	1.06B	902.31M	630.70M	333.00M	228.90M	165.74M
Cash Flow
Free Cash Flow	52.06M	44.95M	44.26M	-103.00M	-71.20M	108.32M
Operating Cash Flow	257.19M	233.02M	220.86M	146.42M	149.49M	233.76M
Investing Cash Flow	-278.74M	-233.07M	-201.47M	-246.95M	-221.51M	-126.24M
Financing Cash Flow	77.48M	397.95M	195.63M	93.65M	104.67M	-45.56M

Radnet Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 78.31
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RDNT, the sentiment is Neutral. The current price of 78.31 is below the 20-day moving average (MA) of 78.56, above the 50-day MA of 76.59, and above the 200-day MA of 62.04, indicating a neutral trend. The MACD of -0.14 indicates Positive momentum. The RSI at 45.07 is Neutral, neither overbought nor oversold. The STOCH value of 15.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RDNT.

Radnet Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RDNT	67 Neutral	$6.05B	-382.69	-1.30%	―	11.09%	-165.89%
SHC	67 Neutral	$4.62B	82.95	10.86%	―	2.67%	-21.96%
RVTY	66 Neutral	$10.67B	47.07	3.04%	0.29%	3.37%	-18.80%
EXAS	62 Neutral	$12.70B	―	-34.54%	―	14.47%	-353.69%
NEO	53 Neutral	$1.29B	―	-12.99%	―	10.10%	-44.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NEOG	51 Neutral	$1.39B	―	-39.71%	―	-2.77%	-4327.53%

Radnet Corporate Events

RadNet Reports Record Revenue and Raises Guidance

RadNet, Inc. is a prominent provider of outpatient diagnostic imaging services in the United States, known for its extensive network of imaging centers and its development of digital health solutions under the DeepHealth brand. In its latest earnings report, RadNet announced a record-breaking third quarter for 2025, with total company revenue reaching $522.9 million, marking a 13.4% increase from the previous year. The company also reported an adjusted EBITDA of $84.9 million, a 15.2% rise compared to the same period in 2024.

RadNet’s Q3 2025 Earnings: Record Revenue & Growth

RadNet, Inc.’s recent earnings call for the third quarter of 2025 conveyed an overall positive sentiment, underscored by record-breaking revenue and adjusted EBITDA. The company showcased significant growth in its advanced imaging and digital health segments, alongside improvements in reimbursement rates and robust financial liquidity. Despite facing challenges in the labor market and slow adoption of certain programs by commercial payers, the sentiment remained optimistic, driven by strong financial performance and strategic growth initiatives.

RadNet Registers Shares for Resale with SEC

On October 21, 2025, RadNet, Inc. filed a prospectus supplement with the SEC to register for resale up to 59,444 shares of its common stock. This move involves the opinion of Reed Smith LLP on the legality of the securities, potentially impacting the company’s market operations by providing liquidity options for selling stockholders.

The most recent analyst rating on (RDNT) stock is a Buy with a $92.00 price target. To see the full list of analyst forecasts on Radnet stock, see the RDNT Stock Forecast page.

RadNet Achieves Record Revenue and Raises 2025 Outlook

RadNet, Inc. is a prominent provider of outpatient diagnostic imaging services in the United States, operating a network of 405 imaging centers and offering radiology information technology and AI solutions under the DeepHealth brand.

RadNet’s Earnings Call: Record Growth and Strategic Advances

RadNet’s latest earnings call paints a picture of robust recovery and growth, with the company achieving record revenue and significant advancements in its digital health and advanced imaging segments. Despite some challenges from earlier in the year, the overall sentiment was positive, highlighting strategic acquisitions and technological deployments that have bolstered operational efficiency.